This work is licensed under the Creative Commons Attribution 4.0 International License.
Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. 2012;36(1):56–9. doi: 10.1053/j.semperi.2011.09.011GhulmiyyahLSibaiBMaternal mortality from preeclampsia/eclampsia201236156910.1053/j.semperi.2011.09.011Open DOISearch in Google Scholar
Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–112. doi: 10.1161/CIRCRESAHA.118.313276RanaSLemoineEGrangerJPKarumanchiSAPreeclampsia: Pathophysiology, challenges, and perspectives20191247109411210.1161/CIRCRESAHA.118.313276Open DOISearch in Google Scholar
Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022;79(2): e21–e41. doi: 10.1161/HYP.0000000000000208GarovicVDDechendREasterlingTKarumanchiSAMcMurtry BairdSMageeLAHypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association2022792e21e4110.1161/HYP.0000000000000208Open DOISearch in Google Scholar
Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome. Hypertension. 2020;75(4):918–26. doi: 10.1161/HYPERTENSIONAHA.119.13763StepanHHundMAndraczekTCombining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome20207549182610.1161/HYPERTENSIONAHA.119.13763Open DOISearch in Google Scholar
Capriglione S, Plotti F, Terranova C, Gulino FA, Di Guardo F, Lopez S, et al. Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. J Matern Fetal Neonatal Med. 2020;33(4):677–86. doi: 10.1080/14767058.2018.1495191CapriglioneSPlottiFTerranovaCGulinoFADi GuardoFLopezSPreeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature20203346778610.1080/14767058.2018.1495191Open DOISearch in Google Scholar
Myatt L. The prediction of preeclampsia: the way forward. Am J Obstet Gynecol. 2022;226(2):S1102–S1107.e8. doi: 10.1016/j.ajog.2020.10.047MyattLThe prediction of preeclampsia: the way forward20222262S1102S1107.e810.1016/j.ajog.2020.10.047Open DOISearch in Google Scholar
Acharya A, Brima W, Burugu S, Rege T. Prediction of preeclampsia-bench to bedside. Curr Hypertens Rep. 2014;16(11):491. doi: 10.1007/s11906-014-0491-3AcharyaABrimaWBuruguSRegeTPrediction of preeclampsia-bench to bedside2014161149110.1007/s11906-014-0491-3Open DOISearch in Google Scholar
McCarthy FP, Ryan RM, Chappell LC. Prospective biomarkers in preterm preeclampsia: a review. Pregnancy Hypertens. 2018;14:72–8. doi: 10.1016/j.preghy.2018.03.010McCarthyFPRyanRMChappellLCProspective biomarkers in preterm preeclampsia: a review20181472810.1016/j.preghy.2018.03.010Open DOISearch in Google Scholar
Giannakou K. Prediction of pre-eclampsia. Obstet Med. 2021;14(4):220–4. doi: 10.1177/1753495X20984015GiannakouKPrediction of pre-eclampsia2021144220410.1177/1753495X20984015Open DOISearch in Google Scholar
Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol. 2018;218(3):287–293.e1. doi: 10.1016/j.ajog.2017.11.561RobergeSBujoldENicolaidesKHAspirin for the prevention of preterm and term preeclampsia: systematic review and meta-analysis20182183287293.e110.1016/j.ajog.2017.11.561Open DOISearch in Google Scholar
Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaithong P, Jaovisidha A, et al. The etiology of preeclampsia. Am J Obstet Gynecol. 2022;226(2):S844–66. doi: 10.1016/j.ajog.2021.11.1356JungERomeroRYeoLGomez-LopezNChaemsaithongPJaovisidhaAThe etiology of preeclampsia20222262S8446610.1016/j.ajog.2021.11.1356Open DOISearch in Google Scholar
Aplin JD, Myers JE, Timms K, Westwood M. Tracking placental development in health and disease. Nat Rev Endocrinol. 2020;16(9):479–94. doi: 10.1038/s41574-020-0372-6AplinJDMyersJETimmsKWestwoodMTracking placental development in health and disease20201694799410.1038/s41574-020-0372-6Open DOISearch in Google Scholar
Li Y, Yan J, Chang HM, Chen ZJ, Leung PCK. Roles of TGF-β superfamily proteins in extravillous trophoblast invasion. Trends Endocrinol Metab. 2021;32(3):170–89. doi: 10.1016/j.tem.2020.12.005LiYYanJChangHMChenZJLeungPCKRoles of TGF-β superfamily proteins in extravillous trophoblast invasion20213231708910.1016/j.tem.2020.12.005Open DOISearch in Google Scholar
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. doi: 10.1080/1364557032000119616ArkseyHO’MalleyLScoping studies: towards a methodological framework200581193210.1080/1364557032000119616Open DOISearch in Google Scholar
Yu L, Li D, Liao QP, Yang HX, Cao B, Fu G, et al. High levels of activin A detected in preeclamptic placenta induce trophoblast cell apoptosis by promoting nodal signaling. J Clin Endocrinol Metab. 2012;97(8):E1370–1379. doi: 10.1210/jc.2011-2729YuLLiDLiaoQPYangHXCaoBFuGHigh levels of activin A detected in preeclamptic placenta induce trophoblast cell apoptosis by promoting nodal signaling2012978E1370137910.1210/jc.2011-2729Open DOISearch in Google Scholar
Baumann M, Bersinger N, Raio L, Albrecht C, Gerber S, Surbek D. Elevated activin A and soluble endoglin serum levels in first trimester harald pre-eclampsia. Am J Obstet Gynecol. 2013;208(1):S271. doi: 10.1016/j.ajog.2012.10.806BaumannMBersingerNRaioLAlbrechtCGerberSSurbekDElevated activin A and soluble endoglin serum levels in first trimester harald pre-eclampsia20132081S27110.1016/j.ajog.2012.10.806Open DOISearch in Google Scholar
Lai J, Pinas A, Syngelaki A, Poon LCY, Nicolaides KH. Maternal serum activin-A at 30–33 weeks in the prediction of pre-eclampsia. J Matern Fetal Neonatal Med. 2013;26(8):733–7. doi: 10.3109/14767058.2012.755167LaiJPinasASyngelakiAPoonLCYNicolaidesKHMaternal serum activin-A at 30–33 weeks in the prediction of pre-eclampsia2013268733710.3109/14767058.2012.755167Open DOISearch in Google Scholar
Tarca AL, Romero R, Benshalom-Tirosh N, Than NG, Gudicha DW, Done B, et al. The prediction of early preeclampsia: results from a longitudinal proteomics study. PloS One. 2019;14(6):e0217273. doi: 10.1371/journal.pone.0217273TarcaALRomeroRBenshalom-TiroshNThanNGGudichaDWDoneBThe prediction of early preeclampsia: results from a longitudinal proteomics study2019146e021727310.1371/journal.pone.0217273Open DOISearch in Google Scholar
Hao S, You J, Chen L, Zhao H, Huang Y, Zheng L, et al. Changes in pregnancy-related serum biomarkers early in gestation are associated with later development of preeclampsia. PloS One. 2020;15(3):e0230000. doi: 10.1371/journal.pone.0230000HaoSYouJChenLZhaoHHuangYZhengLChanges in pregnancy-related serum biomarkers early in gestation are associated with later development of preeclampsia2020153e023000010.1371/journal.pone.0230000Open DOISearch in Google Scholar
Wong GP, Andres F, Walker SP, MacDonald TM, Cannon P, Nguyen TV, et al. Circulating activin A is elevated at 36 weeks’ gestation preceding a diagnosis of preeclampsia. Pregnancy Hypertens. 2022;27:23–6. doi: 10.1016/j.preghy.2021.11.006WongGPAndresFWalkerSPMacDonaldTMCannonPNguyenTVCirculating activin A is elevated at 36 weeks’ gestation preceding a diagnosis of preeclampsia20222723610.1016/j.preghy.2021.11.006Open DOISearch in Google Scholar
Olsen R, Woelkers D, Hull A, LaCoursiere Y. Abnormal second trimester serum analytes are more predictive of earlier and more severe variants of preeclampsia than mild preeclampsia. Am J Obstet Gynecol. 2012;206(1):S261. doi: 10.1016/j.ajog.2012.06.006OlsenRWoelkersDHullALaCoursiereYAbnormal second trimester serum analytes are more predictive of earlier and more severe variants of preeclampsia than mild preeclampsia20122061S26110.1016/j.ajog.2012.06.006Open DOISearch in Google Scholar
Dugoff L, Cuckle H, Behrendt N, Cioffi-Ragan D, Myers L, Hobbins J. First-trimester prediction of preeclampsia using soluble P-selectin, follistatin-related protein 3, complement 3a, soluble TNF receptor type 1, PAPP-A, AFP, inhibin A, placental growth factor, uterine artery Doppler and maternal characteristics. Am J Obstet Gynecol. 2013;208(1):S252. doi: 10.1016/j.ajog.2012.10.755DugoffLCuckleHBehrendtNCioffi-RaganDMyersLHobbinsJFirst-trimester prediction of preeclampsia using soluble P-selectin, follistatin-related protein 3, complement 3a, soluble TNF receptor type 1, PAPP-A, AFP, inhibin A, placental growth factor, uterine artery Doppler and maternal characteristics20132081S25210.1016/j.ajog.2012.10.755Open DOISearch in Google Scholar
Boucoiran I, Thissier-Levy S, Wu Y, Wei SQ, Luo ZC, Delvin E, et al. Risks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies. Am J Perinatol. 2013;30(7):607–12. doi: 10.1055/s-0032-1329691BoucoiranIThissier-LevySWuYWeiSQLuoZCDelvinERisks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies20133076071210.1055/s-0032-1329691Open DOISearch in Google Scholar
Suri S, Muttukrishna S, Jauniaux E. 2D-ultrasound and endocrinologic evaluation of placentation in early pregnancy and its relationship to fetal birthweight in normal pregnancies and pre-eclampsia. Placenta. 2013;34(9):745–50. doi: 10.1016/j.placenta.2013.05.003SuriSMuttukrishnaSJauniauxE2D-ultrasound and endocrinologic evaluation of placentation in early pregnancy and its relationship to fetal birthweight in normal pregnancies and pre-eclampsia20133497455010.1016/j.placenta.2013.05.003Open DOISearch in Google Scholar
Park HJ, Kim SH, Jung YW, Shim SS, Kim JY, Cho YK, et al. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. BMC Pregnancy Childbirth. 2014;14:35. doi: 10.1186/1471-2393-14-35ParkHJKimSHJungYWShimSSKimJYChoYKScreening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy2014143510.1186/1471-2393-14-35Open DOISearch in Google Scholar
Giguère Y, Massé J, Thériault S, Bujold E, Lafond J, Rousseau F, et al. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. BJOG. 2015;122(3):402–10. doi: 10.1111/1471-0528.13050GiguèreYMasséJThériaultSBujoldELafondJRousseauFScreening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers201512234021010.1111/1471-0528.13050Open DOISearch in Google Scholar
Kumer K, Fabjan T, Vodušek VF, Sršen TP, Osredkar J. Assessment of maternal serum inhibin A in normal, preeclamptic and intrauterine growth restricted pregnancies. Clin Chem Lab Med. 2016;54(9):eA127–55. doi: 10.1515/cclm-2016-0624KumerKFabjanTVodušekVFSršenTPOsredkarJAssessment of maternal serum inhibin A in normal, preeclamptic and intrauterine growth restricted pregnancies2016549eA1275510.1515/cclm-2016-0624Open DOISearch in Google Scholar
Chrelias G, Makris GM, Papanota AM, Spathis A, Salamalekis G, Sergentanis TN, et al. Serum inhibin and leptin: risk factors for pre-eclampsia? Clin Chim Acta. 2016;463:84–7. doi: 10.1016/j.cca.2016.10.013ChreliasGMakrisGMPapanotaAMSpathisASalamalekisGSergentanisTNSerum inhibin and leptin: risk factors for pre-eclampsia?201646384710.1016/j.cca.2016.10.013Open DOISearch in Google Scholar
Broumand F, Lak SS, Nemati F, Mazidi A. A study of the diagnostic value of inhibin A tests for occurrence of preeclampsia in pregnant women. Electron Physician. 2018;10(1):6186–92. doi: 10.19082/6186BroumandFLakSSNematiFMazidiAA study of the diagnostic value of inhibin A tests for occurrence of preeclampsia in pregnant women201810161869210.19082/6186Open DOISearch in Google Scholar
Belovic DK, Plešinac S, Dotlić J, Radojević AS, Akšam S, Cvjetićanin MM, et al. Biochemical markers for prediction of hypertensive disorders of pregnancy. J Med Biochem. 2019;38(1): 71–82. doi: 10.2478/jomb-2018-0001BelovicDKPlešinacSDotlićJRadojevićASAkšamSCvjetićaninMMBiochemical markers for prediction of hypertensive disorders of pregnancy2019381718210.2478/jomb-2018-0001Open DOISearch in Google Scholar
Yue CY, Zhang CY, Ni YH, Ying CM. Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome? PloS One. 2020;15(5):e0232634. doi: 10.1371/journal.pone.0232634YueCYZhangCYNiYHYingCMAre serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome?2020155e023263410.1371/journal.pone.0232634Open DOISearch in Google Scholar
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, et al. Establishing a differential marker profile for pregnancy complications near delivery. Fetal Diagn Ther. 2020;47(6):471–84. doi: 10.1159/000502177Sharabi-NovAKumarKFabjan VodušekVPremru SršenTTulNFabjanTEstablishing a differential marker profile for pregnancy complications near delivery20204764718410.1159/000502177Open DOISearch in Google Scholar
Kim YR, Jung I, Park G, Chang SW, Cho HY. First-trimester screening for early preeclampsia risk using maternal characteristics and estimated placental volume. J Matern Fetal Neonatal Med. 2021;34(7):1155–60. doi: 10.1080/14767058.2019.1628207KimYRJungIParkGChangSWChoHYFirst-trimester screening for early preeclampsia risk using maternal characteristics and estimated placental volume202134711556010.1080/14767058.2019.1628207Open DOISearch in Google Scholar
Keikkala E, Forstén J, Ritvos O, Stenman UH, Kajantie E, Hämäläinen E, et al. Serum inhibin-A and PAPP-A2 in the prediction of pre-eclampsia during the first and second trimesters in high-risk women. Pregnancy Hypertens. 2021;25:116–22. doi: 10.1016/j.preghy.2021.05.024KeikkalaEForsténJRitvosOStenmanUHKajantieEHämäläinenESerum inhibin-A and PAPP-A2 in the prediction of pre-eclampsia during the first and second trimesters in high-risk women2021251162210.1016/j.preghy.2021.05.024Open DOISearch in Google Scholar
Garcés MF, Vallejo SA, Sanchez E, Palomino-Palomino MA, Leal LG, Ángel-Muller E, et al. Longitudinal analysis of maternal serum Follistatin concentration in normal pregnancy and preeclampsia. Clin Endocrinol (Oxf). 2015;83(2):229–35. doi: 10.1111/cen.12715GarcésMFVallejoSASanchezEPalomino-PalominoMALealLGÁngel-MullerELongitudinal analysis of maternal serum Follistatin concentration in normal pregnancy and preeclampsia20158322293510.1111/cen.12715Open DOISearch in Google Scholar
Charkiewicz K, Jasinska E, Goscik J, Koc-Zorawska E, Zorawski M, Kuc P, et al. Angiogenic factor screening in women with mild preeclampsia – New and significant proteins in plasma. Cytokine. 2018;106:125–30. doi: 10.1016/j.cyto.2017.10.020CharkiewiczKJasinskaEGoscikJKoc-ZorawskaEZorawskiMKucPAngiogenic factor screening in women with mild preeclampsia – New and significant proteins in plasma20181061253010.1016/j.cyto.2017.10.020Open DOISearch in Google Scholar
Charkiewicz K. Maternal plasma angiogenic factor screening in women with preeclampsia. J Am Soc Hypertens. 2016;10(4): e40–1. doi: 10.1016/j.jash.2016.03.097CharkiewiczKMaternal plasma angiogenic factor screening in women with preeclampsia2016104e40110.1016/j.jash.2016.03.097Open DOISearch in Google Scholar
Nevalainen J, Korpimaki T, Kouru H, Sairanen M, Ryynanen M. Performance of first trimester biochemical markers and mean arterial pressure in prediction of early-onset pre-eclampsia. Metabolism. 2017;75:6–15. doi: 10.1016/j.metabol.2017.07.004NevalainenJKorpimakiTKouruHSairanenMRyynanenMPerformance of first trimester biochemical markers and mean arterial pressure in prediction of early-onset pre-eclampsia20177561510.1016/j.metabol.2017.07.004Open DOISearch in Google Scholar
Luo Q, Han X. Second-trimester maternal serum markers in the prediction of preeclampsia. J Perinat Med. 2017;45(7):809–16. doi: 10.1515/jpm-2016-0249LuoQHanXSecond-trimester maternal serum markers in the prediction of preeclampsia20174578091610.1515/jpm-2016-0249Open DOISearch in Google Scholar
Han X, He J, Wang A, Dong M. Serum follistatin-like-3 was elevated in second trimester of pregnant women who subsequently developed preeclampsia. Hypertens Pregnancy. 2014;33(3):277–82. doi: 10.3109/10641955.2013.874439HanXHeJWangADongMSerum follistatin-like-3 was elevated in second trimester of pregnant women who subsequently developed preeclampsia20143332778210.3109/10641955.2013.874439Open DOISearch in Google Scholar
Purut YE, Buyukbayrak EE, Ercan F, Orcun A, Menke M, Karsidag AYK. Do first trimester maternal serum follistatin-like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes? Clin Exp Obstet Gynecol. 2019;46(2):195–200. doi: 10.12891/ceog4423.2019PurutYEBuyukbayrakEEErcanFOrcunAMenkeMKarsidagAYKDo first trimester maternal serum follistatin-like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?201946219520010.12891/ceog4423.2019Open DOISearch in Google Scholar
Horvath R, Maski M, Zsengeller Z, Lo A, Pernicone E, Rigo J, et al. Follistatin-like 3 protein (FSTL3) is upregulated in preeclampsia. Pregnancy Hypertens. 2016;6(3):144. doi: 10.1016/j.preghy.2016.08.016HorvathRMaskiMZsengellerZLoAPerniconeERigoJFollistatin-like 3 protein (FSTL3) is upregulated in preeclampsia20166314410.1016/j.preghy.2016.08.016Open DOISearch in Google Scholar
Li L, Zheng Y, Zhu Y, Li J. Serum biomarkers combined with uterine artery Doppler in prediction of preeclampsia. Exp Ther Med. 2016;12(4):2515–20. doi: 10.3892/etm.2016.3625LiLZhengYZhuYLiJSerum biomarkers combined with uterine artery Doppler in prediction of preeclampsia201612425152010.3892/etm.2016.3625Open DOISearch in Google Scholar
Xu YT, Shen MH, Jin AY, Li H, Zhu R. Maternal circulating levels of transforming growth factor-β superfamily and its soluble receptors in hypertensive disorders of pregnancy. Int J Gynaecol Obstet. 2017;137(3):246–52. doi: 10.1002/ijgo.12142XuYTShenMHJinAYLiHZhuRMaternal circulating levels of transforming growth factor-β superfamily and its soluble receptors in hypertensive disorders of pregnancy201713732465210.1002/ijgo.12142Open DOISearch in Google Scholar
Knöfler M, Haider S, Saleh L, Pollheimer J, Gamage TKJB, James J. Human placenta and trophoblast development: key molecular mechanisms and model systems. Cell Mol Life Sci. 2019;76(18):3479–96. doi: 10.1007/s00018-019-03104-6KnöflerMHaiderSSalehLPollheimerJGamageTKJBJamesJHuman placenta and trophoblast development: key molecular mechanisms and model systems2019761834799610.1007/s00018-019-03104-6Open DOISearch in Google Scholar
Muttukrishna S. Role of inhibin in normal and high-risk pregnancy. Semin Reprod Med. 2004;22(3):227–34. doi: 10.1055/s-2004-831898MuttukrishnaSRole of inhibin in normal and high-risk pregnancy20042232273410.1055/s-2004-831898Open DOISearch in Google Scholar
Birdsall M, Ledger W, Groome N, Abdalla H, Muttukrishna S. Inhibin A and activin A in the first trimester of human pregnancy. J Clin Endocrinol Metab. 1997;82(5):1557–60. doi: 10.1210/jcem.82.5.3934BirdsallMLedgerWGroomeNAbdallaHMuttukrishnaSInhibin A and activin A in the first trimester of human pregnancy199782515576010.1210/jcem.82.5.3934Open DOISearch in Google Scholar
Bloise E, Ciarmela P, Dela Cruz C, Luisi S, Petraglia F, Reis FM. Activin A in mammalian physiology. Physiol Rev. 2019;99(1): 739–80. doi: 10.1152/physrev.00002.2018BloiseECiarmelaPDela CruzCLuisiSPetragliaFReisFMActivin A in mammalian physiology20199917398010.1152/physrev.00002.2018Open DOISearch in Google Scholar
O’Connor AE. Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Hum Reprod. 1999;14(3):827–32. doi: 10.1093/humrep/14.3.827O’ConnorAESerum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study19991438273210.1093/humrep/14.3.827Open DOISearch in Google Scholar
Welt CK. The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction. Curr Opin Obstet Gynecol. 2002;14(3):317–23. doi: 10.1097/00001703-200206000-00012WeltCKThe physiology and pathophysiology of inhibin, activin and follistatin in female reproduction20021433172310.1097/00001703-200206000-00012Open DOISearch in Google Scholar
Parfenova OK, Kukes VG, Grishin DV. Follistatin-like proteins: structure, functions and biomedical importance. Biomedicines. 2021;9(8):999. doi: 10.3390/biomedicines9080999ParfenovaOKKukesVGGrishinDVFollistatin-like proteins: structure, functions and biomedical importance20219899910.3390/biomedicines9080999Open DOISearch in Google Scholar
Yokoyama Y, Nakamura T, Nakamura R, Irahara M, Aono T, Sugino H. Identification of activins and follistatin proteins in human follicular fluid and placenta. J Clin Endocrinol Metab. 1995;80(3):915–21. doi: 10.1210/jcem.80.3.7883850YokoyamaYNakamuraTNakamuraRIraharaMAonoTSuginoHIdentification of activins and follistatin proteins in human follicular fluid and placenta19958039152110.1210/jcem.80.3.7883850Open DOISearch in Google Scholar
Fullerton PT, Monsivais D, Kommagani R, Matzuk MM. Follistatin is critical for mouse uterine receptivity and decidualization. Proc Natl Acad Sci. 2017;114(24). doi: 10.1073/pnas.1620903114FullertonPTMonsivaisDKommaganiRMatzukMMFollistatin is critical for mouse uterine receptivity and decidualization20171142410.1073/pnas.1620903114Open DOISearch in Google Scholar
Köninger A, Schmidt B, Damaske D, Birdir C, Enekwe A, Kimmig R, et al. Follistatin during pregnancy and its potential role as an ovarian suppressing agent. Eur J Obstet Gynecol Reprod Biol. 2017;212:150–4. doi: 10.1016/j.ejogrb.2017.03.001KöningerASchmidtBDamaskeDBirdirCEnekweAKimmigRFollistatin during pregnancy and its potential role as an ovarian suppressing agent2017212150410.1016/j.ejogrb.2017.03.001Open DOISearch in Google Scholar
Santibañez JF, Quintanilla M, Bernabeu C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 1979. 2011;121(6):233–51. doi: 10.1042/CS20110086SantibañezJFQuintanillaMBernabeuCTGF-β/TGF-β receptor system and its role in physiological and pathological conditions201112162335110.1042/CS20110086Open DOISearch in Google Scholar
Moustakas A, Heldin CH. The regulation of TGFbeta signal transduction. Development. 2009;136(22):3699–714. doi: 10.1242/dev.030338MoustakasAHeldinCHThe regulation of TGFbeta signal transduction200913622369971410.1242/dev.030338Open DOISearch in Google Scholar
Schneider-Kolsky ME, Manuelpillai U, Waldron K, Dole A, Wallace EM. The distribution of activin and activin receptors in gestational tissues across human pregnancy and during labour. Placenta. 2002;23(4):294–302. doi: 10.1053/plac.2002.0787Schneider-KolskyMEManuelpillaiUWaldronKDoleAWallaceEMThe distribution of activin and activin receptors in gestational tissues across human pregnancy and during labour200223429430210.1053/plac.2002.0787Open DOISearch in Google Scholar
Stoikos CJ, Harrison CA, Salamonsen LA, Dimitriadis E. A distinct cohort of the TGFβ superfamily members expressed in human endometrium regulate decidualization. Hum Reprod. 2008;23(6):1447–56. doi: 10.1093/humrep/den110StoikosCJHarrisonCASalamonsenLADimitriadisEA distinct cohort of the TGFβ superfamily members expressed in human endometrium regulate decidualization200823614475610.1093/humrep/den110Open DOISearch in Google Scholar
Li Y, Klausen C, Zhu H, Leung PCK. Activin A increases human trophoblast invasion by inducing SNAIL-mediated MMP2 up-regulation through ALK4. J Clin Endocrinol Metab. 2015;100(11):E1415–27. doi: 10.1210/jc.2015-2134LiYKlausenCZhuHLeungPCKActivin A increases human trophoblast invasion by inducing SNAIL-mediated MMP2 up-regulation through ALK4201510011E14152710.1210/jc.2015-2134Open DOISearch in Google Scholar
Silver HM, Lambert-Messerlian GM, Reis FM, Diblasio AM, Petraglia F, Canick JA. Mechanism of increased maternal serum total activin A and inhibin A in preeclampsia. J Soc Gynecol Investig. 2002;9(5):308–12. doi: 10.1016/s1071-5576(02)00165-xSilverHMLambert-MesserlianGMReisFMDiblasioAMPetragliaFCanickJAMechanism of increased maternal serum total activin A and inhibin A in preeclampsia2002953081210.1016/s1071-5576(02)00165-xOpen DOISearch in Google Scholar
Li Y, Klausen C, Cheng JC, Zhu H, Leung PCK. Activin A, B, and AB increase human trophoblast cell invasion by up-regulating N-Cadherin. J Clin Endocrinol Metab. 2014;99(11):E2216–25. doi: 10.1210/jc.2014-2118LiYKlausenCChengJCZhuHLeungPCKActivin A, B, and AB increase human trophoblast cell invasion by up-regulating N-Cadherin20149911E22162510.1210/jc.2014-2118Open DOISearch in Google Scholar
Zhu S, Li Z, Cui L, Ban Y, Leung PCK, Li Y, et al. Activin A increases human trophoblast invasion by upregulating integrin β1 through ALK4. FASEB J. 2021;35(2). doi: 10.1096/fj.202001604RZhuSLiZCuiLBanYLeungPCKLiYActivin A increases human trophoblast invasion by upregulating integrin β1 through ALK4202135210.1096/fj.202001604ROpen DOISearch in Google Scholar
Kokkinos MI, Murthi P, Wafai R, Thompson EW, Newgreen DF. Cadherins in the human placenta – epithelial–mesenchymal transition (EMT) and placental development. Placenta. 2010;31(9):747–55. doi: 10.1016/j.placenta.2010.06.017KokkinosMIMurthiPWafaiRThompsonEWNewgreenDFCadherins in the human placenta – epithelial–mesenchymal transition (EMT) and placental development20103197475510.1016/j.placenta.2010.06.017Open DOISearch in Google Scholar
Chen J, Khalil RA. Matrix metalloproteinases in normal pregnancy and preeclampsia. Prog Mol Biol Transl Sci. 2017;148: 87–165. doi: 10.1016/bs.pmbts.2017.04.001ChenJKhalilRAMatrix metalloproteinases in normal pregnancy and preeclampsia20171488716510.1016/bs.pmbts.2017.04.001Open DOISearch in Google Scholar
Shu C, Han S, Hu C, Chen C, Qu B, He J, et al. Integrin β1 regulates proliferation, apoptosis, and migration of trophoblasts through activation of phosphoinositide 3 kinase/protein kinase B signaling. J Obstet Gynaecol Res. 2021;47(7):2406–16. doi: 10.1111/jog.14782ShuCHanSHuCChenCQuBHeJIntegrin β1 regulates proliferation, apoptosis, and migration of trophoblasts through activation of phosphoinositide 3 kinase/protein kinase B signaling202147724061610.1111/jog.14782Open DOISearch in Google Scholar
Brkić J, Dunk C, Shan Y, O’Brien JA, Lye P, Qayyum S, et al. Differential role of Smad2 and Smad3 in the acquisition of an endovascular trophoblast-like phenotype and preeclampsia. Front Endocrinol (Lausanne). 2020;11:436. doi: 10.3389/fendo.2020.00436BrkićJDunkCShanYO’BrienJALyePQayyumSDifferential role of Smad2 and Smad3 in the acquisition of an endovascular trophoblast-like phenotype and preeclampsia20201143610.3389/fendo.2020.00436Open DOISearch in Google Scholar
Lim R, Acharya R, Delpachitra P, Hobson S, Sobey CG, Drummond GR, et al. Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am J Obstet Gynecol. 2015;212(1):86.e1–12. doi: 10.1016/j.ajog.2014.07.021LimRAcharyaRDelpachitraPHobsonSSobeyCGDrummondGRActivin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies2015212186.e11210.1016/j.ajog.2014.07.021Open DOISearch in Google Scholar
Hobson SR, Lim R, Mockler JC, Gurusinghe S, Wallace EM. Role of activin A in the pathogenesis of endothelial cell dysfunction in preeclampsia. In: Murthi P, Vaillancourt C, editors. Preeclampsia. New York, NY: Springer, 2018: 39–52. ISBN: 978-1-4939-7498-6HobsonSRLimRMocklerJCGurusingheSWallaceEMRole of activin A in the pathogenesis of endothelial cell dysfunction in preeclampsiaIn:MurthiPVaillancourtCeditors.New York, NYSpringer20183952ISBN: 978-1-4939-7498-6Search in Google Scholar
Shahul S, Ramadan H, Nizamuddin J, Mueller A, Patel V, Dreixler J, et al. Activin A and late postpartum cardiac dysfunction among women with hypertensive disorders of pregnancy hypertension. 2018;72(1):188–93. doi: 10.1161/HYPERTENSIONAHA.118.10888ShahulSRamadanHNizamuddinJMuellerAPatelVDreixlerJ20187211889310.1161/HYPERTENSIONAHA.118.10888Open DOISearch in Google Scholar
Naseem H, Dreixler J, Mueller A, Tung A, Dhir R, Chibber R, et al. Antepartum aspirin administration reduces activin A and cardiac global longitudinal strain in preeclamptic women. J Am Heart Assoc. 2020;9(12):e015997. doi: 10.1161/JAHA.119.015997NaseemHDreixlerJMuellerATungADhirRChibberRAntepartum aspirin administration reduces activin A and cardiac global longitudinal strain in preeclamptic women2020912e01599710.1161/JAHA.119.015997Open DOISearch in Google Scholar
Jones RL. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception. Mol Hum Reprod. 2000;6(12):1107–17. doi: 10.1093/molehr/6.12.1107JonesRLInhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception200061211071710.1093/molehr/6.12.1107Open DOISearch in Google Scholar
Minami S, Yamoto M, Nakano R. Immunohistochemical localization of inhibin/activin subunits in human placenta. Obstet Gynecol. 1992;80(3 Pt 1):410–4.MinamiSYamotoMNakanoRImmunohistochemical localization of inhibin/activin subunits in human placenta1992803 Pt 14104Search in Google Scholar
Bearfield C, Jauniaux E, Groome N, Sargent IL, Muttukrishna S. The secretion and effect of inhibin A, activin A and follistatin on first-trimester trophoblasts in vitro. Eur J Endocrinol. 2005;152(6):909–16. doi: 10.1530/eje.1.01928BearfieldCJauniauxEGroomeNSargentILMuttukrishnaSThe secretion and effect of inhibin A, activin A and follistatin on first-trimester trophoblasts in vitro200515269091610.1530/eje.1.01928Open DOISearch in Google Scholar
Lambert-Messerlian GM, Pinar H, Laprade E, Tantravahi U, Schneyer A, Canick JA. Inhibins and activins in human fetal abnormalities. Mol Cell Endocrinol. 2004;225(1–2):101–8. doi: 10.1016/j.mce.2004.02.019Lambert-MesserlianGMPinarHLapradeETantravahiUSchneyerACanickJAInhibins and activins in human fetal abnormalities20042251–2101810.1016/j.mce.2004.02.019Open DOISearch in Google Scholar
Taché V, Baer RJ, Currier RJ, Li CS, Towner D, Waetjen LE, et al. Population-based biomarker screening and the development of severe preeclampsia in California. Am J Obstet Gynecol. 2014;211(4):377.e1–377.e8. doi: 10.1016/j.ajog.2014.03.026TachéVBaerRJCurrierRJLiCSTownerDWaetjenLEPopulation-based biomarker screening and the development of severe preeclampsia in California20142114377.e1377.e810.1016/j.ajog.2014.03.026Open DOISearch in Google Scholar
Kar M. Role of Biomarkers in early detection of preeclampsia. J Clin Diagn Res. 2014; 8(4): BE01–BE04. doi: 10.7860/JCDR/2014/7969.4261KarMRole of Biomarkers in early detection of preeclampsia201484BE01BE0410.7860/JCDR/2014/7969.4261Open DOISearch in Google Scholar
Fitzgerald B, Levytska K, Kingdom J, Walker M, Baczyk D, Keating S. Villous trophoblast abnormalities in extremely pre-term deliveries with elevated second trimester maternal serum hCG or inhibin-A. Placenta. 2011;32(4):339–45. doi: 10.1016/j.placenta.2011.01.018FitzgeraldBLevytskaKKingdomJWalkerMBaczykDKeatingSVillous trophoblast abnormalities in extremely pre-term deliveries with elevated second trimester maternal serum hCG or inhibin-A20113243394510.1016/j.placenta.2011.01.018Open DOISearch in Google Scholar
Depoix CL, de Selliers I, Hubinont C, Debieve F. HIF1A and EPAS1 potentiate hypoxia-induced upregulation of inhibin alpha chain expression in human term cytotrophoblasts in vitro. Mol Hum Reprod. 2017;23(3):199–209. doi: 10.1093/molehr/gax002DepoixCLde SelliersIHubinontCDebieveFHIF1A and EPAS1 potentiate hypoxia-induced upregulation of inhibin alpha chain expression in human term cytotrophoblasts in vitro201723319920910.1093/molehr/gax002Open DOISearch in Google Scholar
Alldred SK, Takwoingi Y, Guo B, Pennant M, Deeks JJ, Neilson JP, et al. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening. Cochrane Database Syst Rev. 2017;3:CD012599. doi: 10.1002/14651858.CD012599AlldredSKTakwoingiYGuoBPennantMDeeksJJNeilsonJPFirst and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening20173CD01259910.1002/14651858.CD012599Open DOISearch in Google Scholar
Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 2022;226(2S):S1108–19. doi: 10.1016/j.ajog.2020.08.045RolnikDLNicolaidesKHPoonLCPrevention of preeclampsia with aspirin20222262SS11081910.1016/j.ajog.2020.08.045Open DOISearch in Google Scholar
Florio P, Luisi S, Ciarmela P, Severi FM, Bocchi C, Petraglia F. Inhibins and activins in pregnancy. Mol Cell Endocrinol. 2004;225(1):93–100. doi: 10.1016/j.mce.2004.02.018FlorioPLuisiSCiarmelaPSeveriFMBocchiCPetragliaFInhibins and activins in pregnancy200422519310010.1016/j.mce.2004.02.018Open DOISearch in Google Scholar
Hobson SR, Wallace EM, Chan YF, Edwards AG, Teoh MWT, Khaw APL. Mirroring preeclampsia: the molecular basis of Ballantyne syndrome. J Matern Fetal Neonatal Med. 2020;33(5): 768–73. doi: 10.1080/14767058.2018.1500550HobsonSRWallaceEMChanYFEdwardsAGTeohMWTKhawAPLMirroring preeclampsia: the molecular basis of Ballantyne syndrome20203357687310.1080/14767058.2018.1500550Open DOISearch in Google Scholar
Xie J, Xu Y, Wan L, Wang P, Wang M, Dong M. Involvement of follistatin-like 3 in preeclampsia. Biochem Biophys Res Commun. 2018;506(3):692–7. doi: 10.1016/j.bbrc.2018.10.139XieJXuYWanLWangPWangMDongMInvolvement of follistatin-like 3 in preeclampsia20185063692710.1016/j.bbrc.2018.10.139Open DOISearch in Google Scholar
Xu Y, Xie J, Wan L, Wang M, Xu Y, Wang H, et al. Follistatin-like 3, an activin A binding protein, is involved in early pregnancy loss. Biomed Pharmacother. 2020;121:109577. doi: 10.1016/j.biopha.2019.109577XuYXieJWanLWangMXuYWangHFollistatin-like 3, an activin A binding protein, is involved in early pregnancy loss202012110957710.1016/j.biopha.2019.109577Open DOISearch in Google Scholar
Schneyer A, Sidis Y, Xia Y, Saito S, Re E del, Lin HY, et al. Differential actions of follistatin and follistatin-like 3. Mol Cell Endocrinol. 2004;225(1):25–8. doi: 10.1016/j.mce.2004.02.009SchneyerASidisYXiaYSaitoSReE delLinHYDifferential actions of follistatin and follistatin-like 32004225125810.1016/j.mce.2004.02.009Open DOISearch in Google Scholar
Xie J, Zhu H, Chang HM, Klausen C, Dong M, Leung PCK. GDF8 promotes the cell invasiveness in human trophoblasts by upregulating the expression of follistatin-like 3 through the ALK5-SMAD2/3 signaling pathway. Front Cell Dev Biol. 2020;8:573781. doi: 10.3389/fcell.2020.573781XieJZhuHChangHMKlausenCDongMLeungPCKGDF8 promotes the cell invasiveness in human trophoblasts by upregulating the expression of follistatin-like 3 through the ALK5-SMAD2/3 signaling pathway2020857378110.3389/fcell.2020.573781Open DOISearch in Google Scholar
Matsuzaki K. Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis. 2011;32(11): 1578–88. doi: 10.1093/carcin/bgr172MatsuzakiKSmad phosphoisoform signaling specificity: the right place at the right time2011321115788810.1093/carcin/bgr172Open DOISearch in Google Scholar
Adu-Gyamfi EA, Tanam-Djankpa F, Nelson W, Czika A, Kumar-Sah S, Lamptey J, et al. Activin and inhibin signaling: from regulation of physiology to involvement in the pathology of the female reproductive system. Cytokine. 2020;133:155105. doi: 10.1016/j.cyto.2020.155105Adu-GyamfiEATanam-DjankpaFNelsonWCzikaAKumar-SahSLampteyJActivin and inhibin signaling: from regulation of physiology to involvement in the pathology of the female reproductive system202013315510510.1016/j.cyto.2020.155105Open DOISearch in Google Scholar